The Efficacy of NTU 101 Lactic Acid Bacteria Powder in the Adjuvant Improvement of Atopic Dermatitis Clinical Trial
Atopic Dermatitis, Atopic Dermatitis Eczema
About this trial
This is an interventional treatment trial for Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria: - According to the diagnostic criteria of Hanifin & Rajka atopic dermatitis, patients with clinical diagnosis of atopic dermatitis were screened and those who met the following conditions: Age: Children over 6 years old and under 12 years old Patients with moderate atopic dermatitis: SCORAD index 25 - 49.9 (moderate). Atopic dermatitis diagnosed over 6 months Exclusion Criteria: Immunodeficiency: Congenital immunodeficiency: According to the classification principle of "Current classification and status of primary immunodeficiency diseases in Taiwan", it is divided into (1) cellular/T-cell immunodeficiency (2) humoral immunodeficiency (Humoral/B- (3) Complement deficiency (4) Phagocyte deficiency. Human immunodeficiency virus (Human Immunodeficiency Virus, HIV) infection (Inquired from medical records). Other diseases that affect immune function, including kidney disease, diabetes, liver cirrhosis and chronic liver disease, asplenia. Short Bowel Syndrome (Short Bowel Syndrome). Patients with malignant tumors. Patients with central venous catheters. Secondary bacterial infection. Received immunosuppressive and biological agents in the past 3 months (eg: dupilumab, Janus kinase (JAK) inhibitors, Janus kinase inhibitors). Received oral or injectable steroids, antibiotics, and light therapy in the past 1 month. Continuously (3 days or more) take Chinese herbal medicine, probiotic supplements or other fermented foods, such as yogurt, yogurt, and Yakult. Abnormal liver or kidney function (1.5 times higher than normal). Other skin diseases or other systemic diseases. Participated in other clinical trials in the past 3 months.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Probiotic NTU 101 Lactic Acid Bacteria Capsules
Placebo Capsules
The subjects who meet the conditions of this test are randomly assigned according to the ratio of 1:1, and take the lactic acid bacteria NTU 101 (1.8 x 10 ^10 CFU) or Placebo in the test group for a total of 12 weeks of treatment. Once, after the treatment, the test physician evaluated the safety and efficacy of the subjects taking the test group lactobacillus NTU 101.
Maltodextrin was used as a placebo.